The generic name for Gocovri is adagrasib [1].
What is Adagrasib used for?
Adagrasib is a targeted therapy used to treat adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) [1]. This mutation is a common driver of NSCLC [1].
How does Adagrasib work?
Adagrasib is a KRAS G12C inhibitor. It specifically targets and blocks the activity of the KRAS G12C protein, which is a mutated form of a protein that plays a role in cell growth and division [1]. By inhibiting this mutated protein, adagrasib aims to slow or stop the growth of cancer cells that depend on this mutation [1].
When was Adagrasib approved?
The U.S. Food and Drug Administration (FDA) approved adagrasib for use in NSCLC in January 2024 [1].
What is the difference between Gocovri and Adagrasib?
Gocovri is the brand name for the drug whose generic name is adagrasib [1]. Therefore, they are the same medication.
Are there other drugs that target KRAS G12C?
Sotorasib is another KRAS G12C inhibitor that has been approved for treating similar types of non-small cell lung cancer [2].
What are the common side effects of Adagrasib?
Common side effects reported with adagrasib include nausea, diarrhea, fatigue, liver problems, and muscle pain [1]. Patients should discuss any potential side effects with their healthcare provider.
What are the risks associated with Adagrasib?
Potential risks include liver toxicity, interstitial lung disease or pneumonitis (inflammation of the lungs), and heart rhythm problems (QT prolongation) [1]. Monitoring by a healthcare professional is necessary to manage these risks.
What is the pricing of Gocovri (Adagrasib)?
Information on the specific pricing of Gocovri (adagrasib) is best obtained through pharmaceutical provider websites or by consulting with a healthcare insurance provider, as costs can vary based on insurance coverage and location [3].
What is the patent status of Gocovri (Adagrasib)?
Information regarding the patent status and expiration dates for Gocovri (adagrasib) can be found on specialized drug patent tracking websites. DrugPatentWatch.com tracks such information, providing details on patent filings and potential exclusivity periods for medications like adagrasib [4].
Sources:
[1] https://www.drugpatentwatch.com/drugs/adagrasib
[2] https://www.drugpatentwatch.com/drugs/sotorasib
[3] https://www.drugpatentwatch.com/drugs/adagrasib/pricing
[4] https://www.drugpatentwatch.com/drugs/adagrasib/patents